Better Health for All

The company's entire business is devoted to developing pharmaceutical products and therapies for significant health conditions such as obstructive sleep apnea (OSA), rheumatoid arthritis, and generalized anxiety disorder (GAD), which currently have limited or inadequate treatment options.

Clinical trials for IHL-42X (OSA) showed an average 51% reduction in the Apnea-Hypopnea Index (AHI), and for PSX-001 (GAD), 44% of patients achieved at least a 50% reduction in anxiety scores, with 27% achieving remission. As a clinical-stage company, there is no evidence of revenue from products with negative health outcomes. Multiple clinical trials for IHL-42X, PSX-001, and IHL-675A consistently report no serious adverse events, with most adverse events being mild or moderate. For PSX-001, no serious adverse events were reported in a Phase 2 trial. The company is conducting Phase 2 and Phase 3 clinical trials for its drug candidates, including a 560-patient Phase 2/3 trial for IHL-42X and a 73-patient Phase 2 trial for PSX-001. The company has a joint venture with Mind Medicine Australia to expand access to psychedelic-assisted therapies and will serve as a Centre of Excellence for clinician training.

Fair Money & Economic Opportunity

Incannex Healthcare Inc. is a clinical-stage pharmaceutical company focused on developing medicinal cannabis and psychedelic medicine therapies.

The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess financial institutions that lend, insure, move, or store money, and how they democratize access to fair financial services. As Incannex Healthcare Inc. does not engage in these activities or offer consumer financial products, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility (for financial data), fair lending compliance, wealth building outcomes, profit reinvestment (in community finance), financial literacy initiatives, debt burden ratio, geographic inclusion (for financial access points), and product simplicity (for financial products), are not applicable to its business model. Therefore, no evidence could be found to score any of the KPIs against the provided rubric.

Honest & Fair Business

No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business. While Article 4 mentions the disclosure of a Whistleblower Policy and an Anti-Bribery and Corruption Policy, and states that a majority of the board is independent, these are statements of existence or disclosure rather than quantitative metrics or specific details about their strength, enforcement, or performance.

Similarly, the existence of SEC filings or the availability of ESG scores via premium channels does not constitute scorable evidence for transparency or financial reporting KPIs. Therefore, all KPIs are omitted due to lack of specific, measurable evidence.

Kind to Animals

Incannex Healthcare Inc. conducted an animal study using 11 groups of 10 mice, totaling 110 animals, to test its drug cocktail IHL-675A.

Prior to this animal study, the company performed in vitro testing using human cells. The company's actions indicate a policy that permits animal testing, with no explicit ban or strong restrictions evidenced.

Planet-Friendly Business

The company and its subsidiaries are in compliance with all applicable environmental laws.

There have been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of hazardous substances in violation of any law that would result in a Material Adverse Change.

Safe & Smart Tech

No specific, concrete evidence was found in the provided articles regarding Incannex Healthcare Inc.'s data protection, cybersecurity, or responsible AI practices.

The articles primarily discuss financial reporting and Nasdaq listing compliance, which do not provide information relevant to the 'Safe & Smart Tech' KPIs, such as data breaches, AI ethics, cybersecurity investment, privacy certifications, or user data controls.

Zero Waste & Sustainable Products

No specific, concrete data points or initiatives for Incannex Healthcare Inc. (IXHL.US) regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audits, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles.

One article discusses general industry trends and requirements for suppliers in the healthcare plastics sector but does not provide any specific information about IXHL.US's performance or practices. Another article details AstraZeneca's waste and circularity efforts, which are not relevant to IXHL.US.